SCHEMBL20069766

SCHEMBL20069766

CN1CCC(C)(NC(=O)c2cccc(CO)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
SMYD3 Q9H7B4 1/20 0.44
RET P07949 1/20 0.43
CHRM3 P20309 1/20 0.43
MCHR1 Q99705 1/20 0.43
ROCK2 O75116 6/20 0.42
ROCK1 Q13464 1/20 0.42
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
SPHK2 Q9NRA0 1/20 0.41
SPHK1 Q9NYA1 1/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147557 0.86 MCHR1 (0.43) PRMT5WDR77SMYD3RETMCHR1
SCHEMBL20147991 0.86 RET (0.46) RETCHRM3MCHR1ROCK2ROCK1
SCHEMBL20069767 0.86 RET (0.45) PRMT5RETCHRM3MCHR1ROCK2
SCHEMBL20068950 0.82 TP53 (0.52) KMT2APOLB
SCHEMBL20068946 0.82 CYP2C19 (0.61) HDAC6KMT2ACYP2D6CYP2C9CYP2C19
SCHEMBL16565618 0.81 ATM (0.49) MCHR1KMT2A
SCHEMBL20069661 0.80 HCN1 (0.56) MCHR1KMT2ACYP2C9CYP2C19LMNA
SCHEMBL20068952 0.79 DYRK1A (0.45) PRMT5RETHDAC8HDAC6
SCHEMBL18901187 0.77 LOXL2 (0.55) SMYD3ROCK2ROCK1KMT2ASPHK2
SCHEMBL17790246 0.76 ROCK2 (0.52) ROCK2ROCK1HDAC8HDAC6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PRMT5 88/4885WDR77 993/4885SMYD3 1177/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PRMT5 88/4885WDR77 993/4885SMYD3 1177/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 PRMT5 88/4885WDR77 993/4885SMYD3 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.